Clinical Trial: A Study Assessing B-VEC Compared to Matching Placebo for the Treatment and Prevention of Corneal Abrasions in Dystrophic Epidermolysis Bullosa

U.S., June 13 -- ClinicalTrials.gov registry received information related to the study (NCT07016750) titled 'A Study Assessing B-VEC Compared to Matching Placebo for the Treatment and Prevention of Corneal Abrasions in Dystrophic Epidermolysis Bullosa' on May 27.

Brief Summary: B-VEC-EYE-01 is a Phase 3 double-blind, intra-patient crossover study, to evaluate the safety and efficacy of ophthalmic Beremagene Geperpavec (B-VEC) versus matched placebo in pediatric and adult subjects with recurrent corneal abrasions due to dystrophic epidermolysis bullosa (DEB).

Study Start Date: June, 2025

Study Type: INTERVENTIONAL

Condition: Dystrophic Epidermolysis Bullosa DEB - Dystrophic Epidermolysis Bullosa Recessive Dystrophic Epidermolysis Bullos...